Commissioning Chemotherapy Services Conference. Issues of consent in systemic therapy
|
|
- Marianna Moody
- 5 years ago
- Views:
Transcription
1 Commissioning Chemotherapy Services Conference Issues of consent in systemic therapy Dr Janine Mansi Consultant Medical Oncologist 28 th November 2017
2 Introduction Background and context What we have done What we have achieved to date Future plans
3 Background and Context Consent for majority of systemic therapy is mandatory Pharmacists and specialist nurses will not dispense or give treatment unless the consent form has been signed Historically (and in some cases currently) a standard consent form is used for this function
4 Standard Consent Forms Hand written! Variable side-effects included (or not) Quality dependent on clinician taking consent Can just write see patient information sheet No accurate or permanent record of what has been discussed
5 Standard Consent Form
6 Standard consent forms
7 Consent Consent is the principle that a person must give their permission before they receive any type of physical investigation, medical treatment, or personal care reflects the right of patients to determine what happens to their own bodies, and is a fundamental part of good practice. 1
8 Consent Issues Valid consent voluntary, informed, capacity Legal and ethical principles Procedural, NHS and organisational practice guidelines
9 The Law and Ethics The Bolam test (1957): If a doctor reaches the standard of a responsible body of medical opinion, he is not negligent
10 The Law and Ethics Montgomery Case 2015 Montgomery v Lanarkshire: a woman with diabetes and a small stature delivered her son vaginally; he experienced shoulder dystocia, resulting in hypoxic insult with consequent cerebral palsy
11 The Law and Ethics After the Montgomery case, the Bolam test, which asks whether a doctor s conduct would be supported by a responsible body of medical opinion, no longer applies to the issue of consent. The law now requires a doctor to take reasonable care to ensure that the patient is aware of any material risks involved in any recommended treatment, and of any reasonable alternative or variant treatments.
12 The Law and Ethics a patient should be told whatever they want to know, not what the doctor thinks they should be told the most important UK judgement on informed consent in 30 years supports patient autonomy over medical paternalism
13 Patients Clinical Concerns and Ethical Arguments more stringent disclosure requirements would risk overwhelming patients may cause distress may make poor decisions Doctors more lengthy explanations drain on healthcare resources defensive medicine
14 Clinical Concerns and Ethical Arguments The clinician s role is to ensure that relevant information is presented to enable the patient to use it meaningfully Today s patients can expect a more active and informed role in treatment decisions Legally, consent law has been clarified and aligns with current GMC guidance Ethically, it clarifies the existing shift towards a more cooperative approach in the consultation room» Chan et al, BMJ 2017;357:2224
15 Consent for SACT NCAG report 7 Recommendations relating to the whole of the chemotherapy pathway, including consent and information
16 Consent for SACT NCAG report Consent should be obtained and recorded in detail in terms of the aims of treatment and both the common and serious side effects of treatment Main proposed actions Standardised consent forms are used which include details of the toxicities discussed and which identify whether a patient has been provided with written information. Chemotherapy service providers should provide written information to patients about the chemotherapy they will be receiving, the likely side effects and whom they should contact if problems arise (including out of hours). Delivery of such information should be documented. A copy of the consent form should be given to the patient as well as one being filed in the patient s case record.
17 Consent for SACT Peer review Manual for Cancer Services: Chemotherapy Measures
18 Consent forms at GSTT/SEL South East London supported project for development (AW) Guy s and St. Thomas NHS Foundation Trust (GSTT) developed a library of >250 chemotherapy regimenspecific consent forms in Benefits High quality standardised information from clinician to patient Consistent, i.e. no omissions Tool for teaching and training
19 National project Practice of consent for SACT varies in the UK Cancer Research UK (CRUK) awarded a grant to GSTT to host the project Project to develop a national library of SACT regimen-specific consent forms commenced in October 2015 The UK Chemotherapy Board are the governing body for the project:
20 Created the webpage To host the forms and associated documents:
21 Launch July 2016 Published and launched the guidance document First regimen-specific forms for breast cancer, and the generic form in July s to lead chemotherapy clinicians in the UK Communication to members of professional groups (ACP, RCP, RCR, RCPath, UKONS, BOPA) Cancer Research UK news report and tweets
22 National Guidance Recommends the use of regimen-specific forms Guidance for the introduction of the forms Guidance for the process of consent Audit recommendations
23 SACT regimen-specific forms By tumour group for oncology and haematology SACT regimens Reference to SPC, PIL, CRUK and Macmillan drug information sheets Each form is independently checked by an oncology/haematology pharmacist, oncology/haematology consultant and member of the UK Chemotherapy Board
24 5-page form Standard template National Forms
25 Page 1 Hospital name Health professional details Patient details Regimen details Where treatment will be given The intended benefits
26 Page 2 Regimen-specific risks and side effects Separated into common, occasional and rare and other issues Includes a statement that the treatment may be life threatening or even result in death
27 Page 3 Space for other risks Statements confirming discussions Details of leaflets provided Clinician signature Interpreter signature (where appropriate)
28 Page 4 Patient statement and confirmation of consent Further information for patients Whether copy accepted by patient or not
29 Page 5 Guidance for health professionals
30 Published forms Breast July 2016 Generic July 2016 Head and neck cancers October 2016 Melanoma November 2016 Generic immunotherapy December 2016 Gynaecological cancers January 2017 Lung cancers March 2017 Supportive medicines April 2017 Colorectal cancer May 2017 Urology/Bladder cancer July 2017 Thyroid cancer September 2017 Oesophago-gastric and GIST October 2017
31 Communication and Queries Communication updates when new forms published s to lead chemotherapy clinicians in the UK, UK Chemotherapy Board members, and project mailing list Queries Database of all user queries and our responses FAQ document published October 2016 Used to inform development of forms and project
32 Number of visits Evaluation Website analytics (1) 3000 Visits to consent form page by Country UK England N. Ireland Scotland Wales Unknown Other 0 Aug-16 Sep-16 Oct-16 Nov-16 Dec-16 Jan-17 Feb-17 Mar-17 Apr-17 May-17 Jun-17 Jul-17 Aug-17 Sep-17 Month
33 Number of Downloads Evaluation Website analytics (2) Downloads from consent form webpage ( Guidance document Generic SACT form Generic immunotherapy form FAQ document Breast forms Head & neck forms Melanoma forms Gynaecological cancer forms CML forms Lung forms Supportive medicines forms Colorectal forms Urology forms Thyroid forms Month Total
34 January 2017: Evaluation Survey (1) Aims and objectives To evaluate the uptake of the national forms in England, N. Ireland, Scotland and Wales To obtain feedback on the forms To obtain feedback on the challenges related to introducing the forms To use feedback to inform future developments of the project
35 Evaluation Survey (2) Method Survey built using SurveyMonkey, piloted and ed to lead chemotherapy clinicians within NHS hospitals/trusts in the UK in January 2017 Results analysed after 2 weeks Results 87 responses 87% of responses from hospitals/trusts in England 92% aware of national consent forms 74% aware of guidance on consent for SACT
36 Response percent % Evaluation Survey (3) Results (cont.) 50 Method used to consent adult patients to treatment with SACT in the hospital/trust Prior to launch of national forms Following launch of national forms Dept. of Health consent form 1 Local hospital/trust standard consent form Locally developed generic SACT consent form Locally developed SACT regimenspecific consent forms National generic SACT consent form National SACT regimen-specific consent forms
37 Evaluation Survey (4) Results (cont ) 30 hospitals/trusts using forms; 17 plan to use Reasons for not using forms included: o Prefer existing method o Forms not approved in hospital/trust o Resistance from key stakeholders o Too much paper to give to patients o Time and motivation to implement o Use of electronic systems and processes o Forms not available for all tumour groups o Awaiting regional steer on use of national forms o Queries regarding legality of forms
38 Evaluation Survey (5) Conclusions Results give an indication of the awareness and uptake of forms Responses give insight into the benefits and challenges of using the forms Comments positive overall Constructive feedback
39 Evaluation Survey (6) Recommendations Continue to publish forms Outline options for local processes Issue reminder regards national guidance document Continue to send regular updates and comms Legal review of the forms Develop and publish paediatric forms Scope feasibility of electronic forms Repeat survey in 1 year
40 Iterative process Responding to comments Hearing about other practices Extravasation Peripheral neuropathy Haemato-oncology
41 Next steps Forms for the remaining tumour groups will be published in A national steering group is being set up Project evaluation repeat survey Jan/Feb 18 Year 3 Continued maintenance and update of form library Paediatric, TYA and Sarcoma Scope electronic forms Welsh translation of generic forms
42 References Reference guide to consent for examination or treatment: Second edition, Department of Health, Consent: patients and doctors making decisions together, General Medical Council, Sokol D. Update on the UK law on consent. BMJ 2015; 350:h1481. Guidance on consent, General Pharmaceutical Council, The code for nurses and midwives, Nursing and Midwifery Council, Health and Social Care Act 2008 (Regulated Activities) Regulations Care Quality Commission, Chemotherapy Services in England: Ensuring quality and safety, National Chemotherapy Advisory Group, August Manual for Cancer Services Chemotherapy Measures: Version 1.0, National Peer Review Programme, NHS England, April Consent form 1, Department of Health, 2009.
43 Acknowledgements: Acknowledgements Rena Chauhan highly specialist pharmacist Victoria Fashina highly specialist pharmacist (June 2017) Jacky Turner previous lead pharmacist (to 2015) Nisha Shaunak Lead Oncology Pharmacist and Specialised Cancer Commissioning Pharmacist, NHS England (London region) Colleagues at GSTT and Cancer Research UK Members of the UK Chemotherapy Board Tumour specific leads from the CSGs who will help drive the project forward (Steering Group)
Clinical Commissioning Policy: Chemotherapy Algorithms for Adults and Children. January 2013 Reference: NHS England XXX/X/X.
Clinical Commissioning Policy: Chemotherapy Algorithms for Adults and Children January 2013 Reference: NHS England XXX/X/X England 1 NHS England Clinical Commissioning Policy: Chemotherapy Algorithms for
More informationNational Cancer Peer Review Programme
National Cancer Peer Review Programme Julia Hill Acting Deputy National Co-ordinator What is Cancer Peer Review? A quality assurance process for cancer services. An integral part of Improving Outcomes
More informationNational Cancer Peer Review Sarcoma. Julia Hill Acting Deputy National Co-ordinator
National Cancer Peer Review Sarcoma Julia Hill Acting Deputy National Co-ordinator Improving Outcomes Guidance The Intentions of Improving Outcomes for People with Sarcoma Changes in the provision of care
More informationto improve the collection and publication of data on chemotherapy activity, outcomes and costs, the chemotherapy dataset will be introduced
6.19... to improve the collection and publication of data on chemotherapy activity, outcomes and costs, the chemotherapy dataset will be introduced in April 2012 and this should provide commissioners,
More informationHaemato-oncology Clinical Forum. 20 th June 2013
Haemato-oncology Clinical Forum 20 th June 2013 Welcome Dr Majid Kazmi, LCA Haemato-oncology Pathway Group Chair Purpose of today Provide an update on progress of the LCA to date Identify priorities for
More informationOne Palliative Care Annual Report
One 203 Palliative Care Annual Report One In 202, ASCO released a provisional clinical opinion stating that concurrent palliative care should be considered early in the course of advanced or metastatic
More informationNational Cancer Patient Experience Survey Results. East Kent Hospitals University NHS Foundation Trust. Published July 2016
National Cancer Patient Experience Survey 2015 Results East Kent Hospitals University NHS Foundation Trust Published July 2016 Revised 17th August 2016 The National Cancer Patient Experience Survey is
More informationVolunteering in NHSScotland Developing and Sustaining Volunteering in NHSScotland
NG11-07 ing in NHSScotland Developing and Sustaining ing in NHSScotland Outcomes The National Group for ing in NHS Scotland agreed the outcomes below which formed the basis of the programme to develop
More informationFaster Cancer Treatment: Using a health target as the platform for delivering sustainable system changes
Faster Cancer Treatment: Using a health target as the platform for delivering sustainable system changes Organisation Name: Ko Awatea, Counties Manukau Health Presenter: Bob Diepeveen HRT 1520 Innovations
More informationNational Cancer Patient Experience Survey Results. University Hospitals of Leicester NHS Trust. Published July 2016
National Cancer Patient Experience Survey 2015 Results University Hospitals of Leicester NHS Trust Published July 2016 Revised 17th August 2016 The National Cancer Patient Experience Survey is undertaken
More informationBrighton and Sussex University Hospitals NHS Trust Board of Directors. Mark Smith Chief Operating Officer
Meeting: Brighton and Sussex University Hospitals NHS Trust Board of Directors Date: 24 th August 2015 Board Sponsor: Paper Author: Subject: Mark Smith Chief Operating Officer Clinical Director and Directorate
More informationNational Cancer Patient Experience Survey Results. Milton Keynes University Hospital NHS Foundation Trust. Published July 2016
National Cancer Patient Experience Survey 2015 Results Milton Keynes University Hospital NHS Foundation Trust Published July 2016 The National Cancer Patient Experience Survey is undertaken by Quality
More informationCancer Outcomes and Services Dataset: Implications for clinical teams
Cancer Outcomes and Services Dataset: Implications for clinical teams Mick Peake Clinical Lead, NCIN National Clinical Lead, NHS Cancer Improvement Consultant & Senior Lecturer in Respiratory Medicine,
More informationSupra Network Sarcoma Advisory Group (SAG) Annual Report
London and South East Sarcoma Network Supra Network Sarcoma Advisory Group (SAG) Annual Report 2011-2012 Hosted by Date: December 2012 Version: 2 Review Date: September 2013 London Cancer Integrated Cancer
More informationCancer Decision Support Tool (CDS) - FAQ's
Cancer Decision Support Tool (CDS) - FAQ's What is the Cancer Decision Support (CDS) Tool Project? The Cancer Decision Support tool project is part of the wider Prevention and Diagnosis programme of work
More informationPublic Health Wales CDSC Weekly Influenza Surveillance Report Wednesday 21 st January 2015 (covering week )
The The Influenza B in certain countries8 Public Health Wales CDSC Weekly Influenza Surveillance Report Wednesday 21 st January 215 (covering week 3 215) Current level of activity: Low Trend: Decreased
More informationConsultant-led Referral to Treatment (RTT) waiting times collection timetable: outcome of consultation
Consultant-led Referral to Treatment (RTT) waiting times collection timetable: outcome of consultation Summary Between January and March 2014, NHS England consulted on a proposed change to the timetable
More informationSouth Norfolk CCG Dementia Strategy and Action Plan Dr Tony Palframan, SNCCG Governing Body Member
Agenda item: 9.4 Subject: Presented by: Submitted to: South Norfolk CCG Dementia Strategy and Action Plan Dr Tony Palframan, SNCCG Governing Body Member Governing Body Date: 28 th July Purpose of paper:
More informationUsing selective internal radiation therapy to treat bowel cancer that has spread to the liver
Understanding NICE guidance Information for people who use NHS services Using selective internal radiation therapy to treat bowel cancer that has spread to the liver NICE interventional procedures guidance
More information2010 National Survey. University College London Hospitals NHS Foundation Trust
National Cancer Patient Experience Programme 2010 National Survey University College London Hospitals NHS Foundation Trust Published January 2011 The National Cancer Patient Experience Survey Programme
More informationEDINBURGH HEALTHCARE NHS TRUST. 4 Edinburgh Healthcare NHS Trust Printed Material,
Introduction 1 Board Minutes and Papers, 1994-1999 2 Related Board Papers, 1995-2001 3 Administrative Material, 1997-2001, n.d. 4 Edinburgh Healthcare NHS Trust Printed Material, 1995-1997 5 General Strategy
More informationAHP Musculoskeletal Service Redesign. Judith Reid MSc MMACP Consultant Physiotherapist in MSK NHS Ayrshire and Arran
AHP Musculoskeletal Service Redesign Judith Reid MSc MMACP Consultant Physiotherapist in MSK NHS Ayrshire and Arran Local Drivers Routine referral practice Via acute care, duplication Long waiting times
More informationTrust Board of Directors Public. Denise Gale. For Assurance and Information NOT APPLICABLE NOT APPLICABLE NOT APPLICABLE NOT APPLICABLE
NLG(18)014 DATE OF MEETING 30 January 2018 REPORT FOR Trust Board of Directors Public REPORT FROM Richard Sunley, Deputy Chief Executive CONTACT OFFICER Denise Gale SUBJECT Cancer Performance and Backlog
More informationLow back pain and sciatica in over 16s NICE quality standard
March 2017 Low back pain and sciatica in over 16s NICE quality standard Draft for consultation This quality standard covers the assessment and management of non-specific low back pain and sciatica in young
More informationThe Greater Manchester Stroke Operational Delivery Network
The Dr Jane Molloy Clinical Lead What is the GMSODN? Established in July 2015 Only Stroke ODN in the country Non-statutory body constituted from all public sector stroke provider organisations across Greater
More information8 Public Health Wales CDSC Weekly Influenza Surveillance Report Wednesday 21 August 2013 (covering week )
8 Public Health Wales CDSC Weekly Influenza Surveillance Report Wednesday 21 August 213 (covering week 33 213) Current level of activity: Low Trend: Stable compared to last week News: Update Middle East
More informationAsthma Audit Development Project: Hospital pilot information
Asthma Audit Development Project: Hospital pilot information Contents Summary... 1 Pilot process summary 1 Introduction and background... 2 What it will cover 2 Timescales 2 Hospital pilot... 3 Why should
More information2010 National Survey. East Kent Hospitals University NHS Trust
National Cancer Patient Experience Programme 2010 National Survey Published January 2011 The National Cancer Patient Experience Survey Programme is being undertaken by Quality Health on behalf of the Department
More information2010 National Survey. The North West London Hospitals NHS Trust
National Cancer Patient Experience Programme 2010 National Survey Published January 2011 The National Cancer Patient Experience Survey Programme is being undertaken by Quality Health on behalf of the Department
More information2010 National Survey. Royal National Orthopaedic Hospital NHS Trust
National Cancer Patient Experience Programme 2010 National Survey Published January 2011 The National Cancer Patient Experience Survey Programme is being undertaken by Quality Health on behalf of the Department
More information2010 National Survey. The Leeds Teaching Hospitals NHS Trust
National Cancer Patient Experience Programme 2010 National Survey Published January 2011 The National Cancer Patient Experience Survey Programme is being undertaken by Quality Health on behalf of the Department
More informationCancer Outcomes and Services Dataset. What is COSD? Skin Cancers Workshop October 2012
Cancer Outcomes and Services Dataset What is COSD? Skin Cancers Workshop October 2012 17 years ago......cancer registration and careful monitoring of treatment and outcomes are essential... Calman-Hine
More informationFFT and Patient Insight for Improvement. Marie Allen Head of Service User and Carer Experience
FFT and Patient Insight for Improvement Marie Allen Head of Service User and Carer Experience 142 Community Integrated Health and Adult Social Care Teams: District nurses Allied Health Professionals Dental
More informationDorset Cancer Alliance:
Dorset Cancer Alliance: - Structure and Functions - SSG specification Where are we without a Network? Wessex Strategic Cancer Network Individual Trust Cancer Services Dorset CCG Specialised Commissioning
More informationIntegrated Cancer Services Action Plan. Colchester Hospital University NHS Foundation Trust 31 March 2014
Integrated Cancer Services Action Plan Colchester Hospital University NHS Foundation Trust 31 March KEY Implemented, clearly evidenced and externally approved On Track to deliver Some issues narrative
More informationUnderstanding lymphoma: the importance of patient data
Understanding lymphoma: the importance of patient data Introduction what is a cancer registry and why is it important? Cancer registries collect detailed, personalised information and data about cancer
More information2010 National Survey. Northern Lincolnshire and Goole Hospitals NHS Foundation Trust
National Cancer Patient Experience Programme 2010 National Survey Northern Lincolnshire and Goole Hospitals NHS Foundation Trust Published January 2011 The National Cancer Patient Experience Survey Programme
More informationPATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Pembrolizumab PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:
More informationReferral to treatment (RTT) waiting times statistics for consultant-led elective care 2014 Annual Report
Referral to treatment (RTT) waiting times statistics for consultant-led elective care 2014 Annual Report 1 Referral to treatment (RTT) waiting times statistics for consultant-led elective care 2014 Annual
More informationFAQs about Provider Profiles on Breast Cancer Screenings (Mammography) Q: Who receives a profile on breast cancer screenings (mammograms)?
FAQs about Provider Profiles on Breast Cancer Screenings (Mammography) Q: Who receives a profile on breast cancer screenings (mammograms)? A: We send letters and/or profiles to PCPs with female members
More informationThe Future of the Peer Review Programme
The Future of the Peer Review Programme The future of the programme has been in some considerable doubt. However thanks to the support of: Sean Duffy National Clinical Lead for Cancer, James Palmer Clinical
More informationROLE SPECIFICATION FOR MACMILLAN GPs
ROLE SPECIFICATION FOR MACMILLAN GPs November 2010 History of Macmillan GPs Macmillan Cancer Support has funded GP positions from the early 1990 s, following the success of our investment in supporting
More informationPATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Carboplatin-Etoposide PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL
More informationAcute Heart Failure. Study protocol
Acute Heart Failure Study protocol Study Advisory Group Lisa Anderson Cardiologist St Georges Joanne Bateman Lead pharmacist for cardiology Countess of Chester Paul Foley Cardiologist Swindon Jane Greaves
More informationLeeds West CCG Paediatric asthma project. January 2015-January 2017
Leeds West CCG Paediatric asthma project. January 2015-January 2017 Aims to raise asthma awareness improve care reduce emergency attendances and unplanned admissions to secondary care for children with
More informationPATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: BEP (5 day) PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:
More informationAdvance Statements. What is an Advance Statement? Information Line: Website: compassionindying.org.uk
Information Line: 0800 999 2434 Website: compassionindying.org.uk This factsheet explains what an Advance Statement is and how to make one. It is for people living in England and Wales. If you live in
More informationBreast Test Wales Screening Division Public Health Wales
Breast Test Wales Screening Division Public Health Wales Programme Level Agreement with Welsh Government Quarterly Report October - December Breast Test Wales - Quarterly Report October - December Service
More informationAudit Report. National Audit of Paediatric Radiology Services in Hospitals
Audit Report National Audit of Paediatric Radiology Services in Hospitals www.rcr.ac.uk 2 Contents Introduction 3 Standards 4 Material and methods 5 Results 6 Discussion 8 References 10 www.rcr.ac.uk 3
More informationThe NHS Cancer Plan: A Progress Report
DEPARTMENT OF HEALTH The NHS Cancer Plan: A Progress Report LONDON: The Stationery Office 9.25 Ordered by the House of Commons to be printed on 7 March 2005 REPORT BY THE COMPTROLLER AND AUDITOR GENERAL
More informationNorth of England Cancer Network. Policies and Procedures. Standards for the Safe Use of Oral Anticancer Medicines
\ North of England Cancer Network Policies and Procedures Standards for the Safe Use of Oral Anticancer Medicines NECN Oral Anticancer medicine Policy version 1.6 Page 1 of 17 Issue Date: Feb 2017 Contents
More informationTotal Payment for sponsored attendances by Healthcare Professionals: 182,677 ( 153,923 in 2013)
Gilead Sciences Ltd. 280 High Holborn London WC1V 7EE 31st March 2015 Relationships with Healthcare Professionals in the United Kingdom Gilead Sciences makes payments to Healthcare Professionals for consultancy
More informationPATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Zoledronic acid PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:
More informationPATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Ponatinib PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:
More informationPATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Docetaxel-EC PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:
More informationESPA Directorate KPI Report: Quarter 1,
ESPA Directorate KPI : 2015 2016 Quarter 1, Compiled by ESPA Operations Manager The Key Performance Indicators (KPIs) detailed in this report give direction to the ESPA Directorate and its activities.
More informationTRANSFORMING STROKE CARE IN THE CAPITAL: THE LONDON STROKE STRATEGY
TRANSFORMING STROKE CARE IN THE CAPITAL: THE LONDON STROKE STRATEGY LUCY GROTHIER Director South London Cardiac and Stroke Network lucy.grothier@slcsn.nhs.uk 27 th May 2011 Gaps in London stroke care GAPS
More informationPATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Atezolizumab PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:
More informationViolent Crime Prevention Board Strategy. 26 September Violent Crime Prevention using Vision to Champion Progress
Violent Crime Prevention Board Strategy 26 September 2018 Violent Crime Prevention using Vision to Champion Progress Page2 Violent Crime Prevention Board (VCPB) Strategy 2018 to 2023 1. Introduction This
More informationNHS. High dose rate brachytherapy for carcinoma of the cervix. National Institute for Health and Clinical Excellence. Issue date: March 2006
NHS National Institute for Health and Clinical Excellence Issue date: March 2006 High dose rate brachytherapy for carcinoma of Understanding NICE guidance information for people considering the procedure,
More information18 Week 92% Open Pathway Recovery Plan and Backlog Clearance
18 Week 92% Open Pathway Recovery Plan and Backlog Clearance Page 1 of 6 17.05.2012 1.0 Background 18-Week 92% Open Pathway RECOVERY PLAN The Trust has achieved compliance against the admitted and non-admitted
More informationSCOTTISH CANCER REFERRAL GUIDELINES REVIEW 2018
SCOTTISH CANCER REFERRAL GUIDELINES REVIEW 2018 Dr Peter Hutchison, Chair of Review Group WHAT & WHY? Scottish Cancer Referral Guidelines 2014 Scottish Primary Care Cancer Group identified need for some
More informationPATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: FEC-P PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP: MALE
More informationImpact of National Guidance for Drug Prescribing for Dentistry
Impact of National Guidance for Drug Prescribing for Dentistry Samantha Rutherford Jan Clarkson, Doug Stirling, Linda Young, Paula Elouafkaoui, Anna Templeton, Craig Ramsay on behalf of the TRiaDS methodology
More informationNewsleTTer. ISSUe 8 DETECT CANCER EARLY
DETECT CANCER EARLY NewsleTTer. ISSUe 8 Scottish Referral Guidelines for Suspected Cancer. The Scottish Referral Guidelines for Suspected Cancer have been refreshed and were launched on 4 September. They
More informationMonitoring Protocol for Clozapine-induced Myocarditis. Copyright 2017, CAMH
1 Monitoring Protocol for Clozapine-induced Myocarditis 1 Agenda Problem Identification / Identification Importance / Importance Baseline Workflow Baseline Workflow Baseline Data Baseline Data Objectives
More informationWatching and waiting : what it means for patients. Dr Christian Aldridge Consultant Dermatologist Cwm Taf NHS Trust
Watching and waiting : what it means for patients Dr Christian Aldridge Consultant Dermatologist Cwm Taf NHS Trust Watching and waiting or...watching and worrying Once you have a cancer diagnosis, you
More informationDear Colleague SUPPLEMENTARY INFORMATION ON CANNABIS BASED PRODUCTS FOR MEDICINAL USE
Directorate of Chief Medical Officer T: 0131-244 2470 E: John.Hannah@gov.scot Dear Colleague SUPPLEMENTARY INFORMATION ON CANNABIS BASED PRODUCTS FOR MEDICINAL USE Following my letter of 31 October 2018
More informationPATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Oxaliplatin- Fluorouracil (FOLFOX) PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier)
More informationCancer Chemotherapy in Clinical Practice
Cancer Chemotherapy in Clinical Practice Cancer Chemotherapy in Clinical Practice Terry Priestman Terry Priestman, MD, FRCP, FRCR New Cross Hospital Wolverhampton UK British Library Cataloguing in Publication
More informationPatient Information Forum
Patient Information Forum Nov 2010 - Update Apologies for cancelling our October meeting (due to unforeseen circumstances). Our next meeting is on 14 December, 9:30am-12:30pm, Seminar Room 2, Cancer Centre,
More informationCommissioning Cancer Services. Andy McMeeking RCGP/NCIN Primary Care Workshop, 13 th February 2013
Commissioning Cancer Services Andy McMeeking RCGP/NCIN Primary Care Workshop, 13 th February 2013 The Health & Social Care Bill (27 th March 2012) Two New Organisations NHS Commissioning Board (NHS CB)
More informationCosting report: Lipid modification Implementing the NICE guideline on lipid modification (CG181)
Putting NICE guidance into practice Costing report: Lipid modification Implementing the NICE guideline on lipid modification (CG181) Published: July 2014 This costing report accompanies Lipid modification:
More informationBritish Association of Stroke Physicians Strategy 2017 to 2020
British Association of Stroke Physicians Strategy 2017 to 2020 1 P age Contents Introduction 3 1. Developing and influencing local and national policy for stroke 5 2. Providing expert advice on all aspects
More informationfor healthcare professionals
Fertility toolkit for healthcare professionals We ve developed this toolkit for setting up a fertility referral pathway for young women with breast cancer at the point of diagnosis. We want to help improve
More informationActivity Report April 2013 March 2014
North, South East and West of Scotland Cancer Networks Sarcoma National Managed Clinical Network Activity Report April 2013 March 2014 Dr Jeff White Consultant Oncologist NMCN Clinical Lead Lindsay Campbell
More informationNCT practitioners can help improve maternity services for all women
Issue 38 March 2018 perspective SERVICE DEVELOPMENT & POLICY Contents >> NCT s journal on preparing parents for birth and early parenthood NCT practitioners can help improve maternity services for all
More informationMental Health Collaborative. Dementia Summary of Activity. April 2010
Mental Health Collaborative Dementia Summary of Activity April 2010 The following extracts provide either one example of a Board s dementia improvement activity or a brief summary of a Board s current
More informationNational Cancer Patient Experience Programme. 2012/13 National Survey. East Kent Hospitals University NHS Foundation Trust. Published August 2013
National Cancer Patient Experience Programme 2012/13 National Survey Published August 2013 The National Cancer Patient Experience Survey Programme is being undertaken by Quality Health on behalf of NHS
More informationNational Breast Cancer Audit next steps. Martin Lee
National Breast Cancer Audit next steps Martin Lee National Cancer Audits Current Bowel Cancer Head & Neck Cancer Lung cancer Oesophagogastric cancer New Prostate Cancer - undergoing procurement Breast
More informationSimply, participation means individual s involvement in decisions that affect them.
Simply, participation means individual s involvement in decisions that affect them. NHS England guidance on participation sets out two types of participation in healthcare: 1) people s involvement in decisions
More informationDiabetes is a lifelong, chronic. Survey on the quality of diabetes care in prison settings across the UK. Keith Booles
Survey on the quality of diabetes care in prison settings across the UK Article points 1. The Royal College of Nursing Diabetes Forum conducted an audit of prisons within the UK to determine the level
More informationSymptom Control During Chemotherapy (SCDC) MN Community Measurement
Symptom Control During Chemotherapy (SCDC) MN Community Measurement MN Community Measurement Nonprofit health care quality improvement and reporting organization Specialize in developing, collecting, analyzing
More informationNational Cancer Patient Experience Programme National Survey. Royal National Orthopaedic Hospital NHS Trust. Published September 2014
National Cancer Patient Experience Programme 2014 National Survey Royal National Orthopaedic Hospital NHS Trust Published September 2014 The National Cancer Patient Experience Survey Programme is undertaken
More informationMDT IMPROVEMENT PROJECT. Professor Muntzer Mughal, UCLH
MDT IMPROVEMENT PROJECT Professor Muntzer Mughal, UCLH 1995..assessment and management of rare cancers in multidisciplinary teams.. 2000 the care of all patients with cancer should be formally reviewed
More informationKeeping control What you should expect from your NHS bladder and bowel service
Keeping control What you should expect from your NHS bladder and bowel service Based on findings from the national audit of continence care 2010 National audit funded by: Report authors Dr Danielle Harari
More informationPATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Docetaxel-Oxaliplatin- Fluorouracil (FLOT) PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other
More informationPATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Cisplatin- Capecitabine- Trastuzumab PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier)
More informationCancer Waiting Times in NHSScotland
Cancer Waiting Times in NHSScotland 1 October to 31 December 2017 Publication date 27 March 2018 A National Statistics publication for Scotland This is a National Statistics Publication National Statistics
More informationPATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Nintedanib-Docetaxel PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL
More informationCANCER IN SCOTLAND: ACTION FOR CHANGE The structure, functions and working relationships of Regional Cancer Advisory Groups
CANCER IN SCOTLAND: ACTION FOR CHANGE The structure, functions and working relationships of Regional Cancer Advisory Groups Introduction/Background 1. Our National Health: A Plan for action, a plan for
More informationFuture Direction for Cancer Registries
Future Direction for Cancer Registries Sally Vernon Head of Quality and Analysis Eastern Cancer Registry and Information Centre sally.vernon@ecric.nhs.uk In Ye Olde Days. 8 regional cancer registries Variation
More informationHow a Signs of Safety approach is changing practice in Norfolk. Andrea Brown Principal Social Worker Community Care- Live Tuesday 10 th May 2016
How a Signs of Safety approach is changing practice in Norfolk Andrea Brown Principal Social Worker Community Care- Live Tuesday 10 th May 2016 The Norfolk Context 2014 OFSTED What did we need to do? Address
More informationPATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Bevacizumab + Chemotherapy PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL
More informationWaiting Times for Suspected and Diagnosed Cancer Patients
Waiting Times for Suspected and Diagnosed Cancer Patients 2015-16 Annual Report Waiting Times for Suspected and Diagnosed Cancer Patients 1 Waiting Times for Suspected and Diagnosed Cancer Patients Prepared
More informationDCP Newsletter. Welcome. Issue 1 June Key Dates. National Men s Health Week June 2018
DCP Newsletter Issue 1 June 2018 Welcome Hello and a warm welcome to all of our readers of this first edition of the Dorset Cancer Partnership (DCP) newsletter. Each edition of this newsletter will provide
More information